Exabis Library
Welcome to the e-CCO Library!
P0582: Do we need a Structured Transition Programme for patients with IBD? The Irish Experience
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0583: The Effects of a Dual-Strain Probiotic Versus Placebo on Cytokine Levels in Patients with Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0584: Rituximab versus infliximab for the treatment of PR3-ANCA Positive Moderately to Severely Active Ulcerative Colotis: A retrospective Multicentre Real-World Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0585: A treat to target approach in IBD: contemporary real-world perspectives from an international survey
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0586: Nationwide population-based cohort study on the use and persistence of infliximab (IV and SC) in France: the Riposte IBD study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0587: Effectiveness and safety of Risankizumab in Crohn’s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0588: Efficacy and health-related quality of life associated with second-line vedolizumab after one prior first-line anti-tumour necrosis factor treatment in patients with active ulcerative colitis: A meta-analysis of the GEMINI-1 and VISIBLE-1 trials
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0589: High treatment persistence following infliximab dose escalation in Inflammatory Bowel Disease: A real world study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P058: Bacterial activation of thioguanine results in lymphocyte independent improvement in murine colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P058: Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P058: Do circulating exosomes interfere with vedolizumab efficacy in IBD patients?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P058: IL-36 signaling in Crohn’s disease – characterization of a patient with an IL36RA mutation
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P058: Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P058: Phosphodiesterase 8A domains at the site of leucocyte–endothelial cell adhesion in ulcerative colitis submucosa
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P058: Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P059 Cytokine responsive transcriptional networks in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0590: Long term outcomes of biologic therapy for the treatment of prepouch ileitis: a multi-centre multi-national retrospective study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0591: Janus Kinase Inhibitors Improve Liver Biochemistry in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: an ECCO CONFER Study.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0592: Safety of the Adjuvant Recombinant Herpes Zoster Vaccine in Crohn’s Disease and Ulcerative Colitis: A Real-World Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0593: High-dose Tofacitinib in Acute Severe Ulcerative Colitis: an option to avoid colectomy?
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM